Physician profile
Jeffrey K Brummer
NPI 1265417851
$2,616.63
in general payments reported to CMS, 2019-2025
34 companies · $583 in 2025
The $583 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $28.63 · 2021: $74.61 · 2022: $172 · 2023: $430 · 2024: $660 · 2025: $583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,673.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $697.49 | 2019-2025 | Puraply, Puraply Wound Matrix, Apligraf |
| Kerecis Limited | $165.70 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Amgen INC. | $158.53 | 2019-2024 | Repatha |
| Abbvie INC. | $137.13 | 2022-2025 | Vraylar |
| Novo Nordisk INC | $133.82 | 2019-2025 | Wegovy |
| Tactile Systems Technology INC | $127.94 | 2019-2025 | Flexitouch Plus, Nimbl |
| Osiris Therapeutics INC. | $120.18 | 2019 | |
| Smith+Nephew, INC. | $119.59 | 2019-2025 | Collagenase Santyl, Grafix Pl, Pico 7 |
| Next Science LLC | $114.18 | 2023 | Xperience, Blastx, Surgx |
| Musculoskeletal Transplant Foundation INC. | $87.55 | 2022 | |
| Merck Sharp & Dohme LLC | $84.54 | 2024-2025 | Vaxneuvance, Capvaxive, Vaxelis |
| Pfizer INC. | $77.73 | 2019-2025 | |
| Medtronic, INC. | $62.84 | 2021 | |
| Phathom Pharmaceuticals, INC. | $61.82 | 2024 | Voquezna |
| Ironshore Pharmaceuticals INC. | $51.25 | 2023-2024 | Jornay Pm |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $46.90 | 2022-2025 | Jardiance, Zepbound, Mounjaro |
| Acadia Pharmaceuticals INC | $44.30 | 2019-2024 | Daybue |
| Solventum Corporation | $34.85 | 2025 | Activ.A.C. |
| Paratek Pharmaceuticals, INC. | $29.05 | 2024-2025 | Nuzyra |
| Viatris Specialty LLC | $23.98 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $21.69 | 2024 | Keveyis |
| Lundbeck LLC | $21.18 | 2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $20.42 | 2023 | |
| Sanofi-Aventis U.S. LLC | $20.26 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.86 | 2024 | Rexulti |
| Sanofi Pasteur INC. | $18.77 | 2022 | |
| Seqirus USA INC | $17.63 | 2024 | Fluad, Flucelvax |
| Glaxosmithkline, LLC. | $15.69 | 2024 | Arexvy, Shingrix |
| Kowa Pharmaceuticals America, INC. | $15.60 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.65 | 2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $14.19 | 2019 | |
| Allergan, INC. | $13.42 | 2019 | |
| Amarin Pharma, INC. | $13.16 | 2020 | |
| Medtronic Minimed, INC. | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Brummer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.